Sign up to save your podcasts
Or
Share 322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.
View all episodes
By STAT
4.6
300300 ratings
STAT reporter Matt Herper joins us to break down all the angles of this week's tumultuous week in cancer immunotherapy, including his up-close look at Summit co-CEO Bob Duggan. We also discuss the latest news in the life sciences, including Moderna pruning its pipeline and its spending, plus results from a study that tested a GLP-1 drug in children.
More shows like The Readout Loud
View all
WSJ Tech News Briefing
1,641 Listeners
WSJ What’s News
4,310 Listeners
The Daily
111,673 Listeners
KFF Health News' 'What the Health?'
469 Listeners
The Long Run with Luke Timmerman
117 Listeners
The Journal.
5,905 Listeners
Morning Brew Daily
2,929 Listeners
Tradeoffs
384 Listeners
Biotech 2050 Podcast
60 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
31 Listeners
Raising Health
141 Listeners
Biotech Hangout
9 Listeners
ACQ2 by Acquired
193 Listeners
Ground Truths
43 Listeners